Profile data is unavailable for this security.
About the company
Vicapsys Life Sciences, Inc. develops and commercializes, on a worldwide basis, various intellectual property rights relating to a series of encapsulated products that incorporate proprietary derivatives of the chemokine CXCL12 for creating a zone of immunoprotection around cells, tissues, organs and devices for therapeutic purposes. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. It also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.
- Revenue in USD (TTM)0.00
- Net income in USD-1.08m
- Incorporated1997
- Employees2.00
- LocationVicapsys Life Sciences Inc1735 Buford Highway, Ste. 215-113CUMMING 30041United StatesUSA
- Phone+1 (470) 514-4013
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coeptis Therapeutics Holdings Inc | 0.00 | -21.27m | 13.19m | 5.00 | -- | 2.91 | -- | -- | -0.8922 | -0.8922 | 0.00 | 0.1221 | 0.00 | -- | -- | 0.00 | -266.05 | -36.90 | -392.90 | -37.81 | -- | -- | -- | -- | -- | -- | 0.2068 | -- | -- | -- | 43.40 | -- | -- | -- |
| GlucoTrack Inc | 0.00 | -7.10m | 13.43m | 6.00 | -- | 3.20 | -- | -- | -0.3394 | -0.3394 | 0.00 | 0.153 | 0.00 | -- | -- | 0.00 | -193.30 | -94.01 | -294.60 | -142.35 | -- | -- | -- | -10,447.96 | -- | -- | 0.0578 | -- | -- | -- | -60.02 | -- | -- | -- |
| Organovo Holdings Inc | 242.00k | -19.09m | 13.51m | 15.00 | -- | 1.66 | -- | 55.83 | -2.17 | -2.17 | 0.0275 | 0.6283 | 0.0143 | -- | 4.44 | 12,100.00 | -112.40 | -51.24 | -123.59 | -54.90 | -- | -- | -7,886.36 | -1,269.78 | -- | -- | 0.00 | -- | -75.33 | -39.60 | -50.76 | -- | 5.99 | -- |
| Pieris Pharmaceuticals Inc | 42.81m | -24.54m | 13.91m | 46.00 | -- | 0.52 | -- | 0.325 | -22.94 | -22.94 | 38.03 | 21.64 | 0.6382 | -- | 13.42 | 930,652.20 | -36.58 | -28.41 | -57.30 | -39.69 | -- | -- | -57.33 | -94.61 | -- | -- | 0.00 | -- | 65.28 | 8.03 | 26.25 | -- | -36.82 | -- |
| Microbot Medical Inc | 0.00 | -10.26m | 13.93m | 22.00 | -- | 2.26 | -- | -- | -0.8926 | -0.8926 | 0.00 | 0.4283 | 0.00 | -- | -- | 0.00 | -151.13 | -53.28 | -183.85 | -62.65 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18.44 | -- | -31.76 | -- |
| Vicapsys Life Sciences Inc | 0.00 | -1.08m | 14.24m | 2.00 | -- | -- | -- | -- | -0.0327 | -0.0327 | 0.00 | -0.0416 | 0.00 | -- | -- | 0.00 | -364.66 | -- | -- | -- | -- | -- | -- | -- | -- | -10.40 | -- | -- | -- | -- | -317.25 | -- | -- | -- |
| Nexgel Inc | 4.09m | -3.16m | 14.26m | 19.00 | -- | 2.80 | -- | 3.49 | -0.5566 | -0.5566 | 0.7212 | 0.818 | 0.4027 | 3.81 | 9.57 | 215,263.20 | -31.39 | -44.61 | -38.80 | -56.19 | 15.16 | 5.02 | -77.95 | -180.98 | 1.46 | -- | 0.1396 | -- | 99.66 | 13.06 | 33.48 | -- | -- | -- |
| Edesa Biotech Inc | 0.00 | -7.25m | 14.54m | 16.00 | -- | 3.36 | -- | -- | -2.37 | -2.37 | 0.00 | 1.34 | 0.00 | -- | -- | 0.00 | -84.50 | -- | -107.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.28 | -- | -- | -- |
| Trinity Biotech plc (ADR) | 56.83m | -36.87m | 14.86m | 380.00 | -- | -- | -- | 0.2615 | -4.82 | -3.14 | 7.42 | -15.67 | 0.7501 | 1.76 | 3.83 | 149,557.90 | -48.66 | -20.30 | -61.88 | -29.54 | 34.22 | 39.92 | -64.87 | -29.86 | 1.27 | -1.61 | 1.55 | -- | -9.10 | -10.15 | 15.41 | -- | -31.08 | -- |
| Oncotelic Therapeutics Inc | 70.00k | -7.90m | 14.95m | 22.00 | -- | 1.23 | -- | 213.57 | -0.02 | -0.02 | 0.0002 | 0.0304 | 0.0021 | -- | 3.61 | 3,181.82 | -24.82 | -25.03 | -49.08 | -48.76 | -- | -- | -11,722.94 | -1,692.93 | -- | -0.4788 | 0.5199 | -- | -- | -- | -255.12 | -- | -- | -- |
| Mannatech Inc | 131.96m | -2.24m | 14.98m | 213.00 | -- | 1.41 | -- | 0.1136 | -1.21 | -1.21 | 70.53 | 5.64 | 2.92 | 1.99 | 854.08 | 619,507.10 | -4.96 | 4.39 | -12.90 | 9.16 | 77.95 | 77.87 | -1.70 | 1.72 | 0.5093 | -5.81 | 0.1226 | 88.33 | -3.83 | -5.33 | 50.13 | -- | -20.38 | -- |
| Kiora Pharmaceuticals Inc | 16.00m | 2.28m | 15.27m | 12.00 | -- | 0.4374 | 6.57 | 0.9543 | -1.60 | -1.60 | 1.21 | 1.33 | 0.5427 | -- | 8.64 | 1,333,333.00 | 9.52 | -70.52 | 10.17 | -81.86 | -- | -- | 17.55 | -2,040.61 | -- | -- | 0.00 | -- | -- | -- | 3.97 | -- | -- | -- |
| Nascent Biotech Inc | 0.00 | -2.09m | 15.28m | -- | -- | 500.02 | -- | -- | -0.0147 | -0.0147 | 0.00 | 0.0002 | 0.00 | -- | -- | -- | -346.80 | -815.53 | -- | -- | -- | -- | -- | -548.75 | -- | -- | 0.8045 | -- | -100.00 | -- | -495.46 | -- | -- | -- |
